Physician

Kenneth James Minielly, M.D.

According to 2025 Medicare claims, Kenneth Minielly, M.D. (NPI: 1699125062) practices dermatology in the Bowling Green, KY market, with the plurality of this provider's patient population coming from Warren, KY. This provider's primary affiliated billing organization is KENTUCKY SKIN CANCER CENTER PLLC (NPI: 1902302987; TIN: 824928891) and primary practice location at 42103-9998.

Minielly's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,603 traditional Medicare patients, billed 9,051 HCPCS/CPT codes, and received $349,834 in Medicare payments. The top billing code was 11106 (Incision biopsy, first skin growth). Part D data shows 1,957 prescription claims across 699 beneficiaries totaling $2,200,484 in drug costs, led by Tremfya (Guselkumab). Open Payments data shows 71 records totaling $1,609. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $41,261 to $349,834. Similarly, Part D prescription costs have risen steadily, from $3,322 to $2,200,484. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$175K$350K2020 Medicare payment: $41,261 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $197,711 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $278,221 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $288,974 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $349,834 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
2020212919$41,261
20218025,024$197,711
20221,2656,850$278,221
20231,4147,981$288,974
20241,6039,051$349,834

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$1.1M$2.2M2016 Drug cost: $3,322 (USD; Tot_Drug_Cst)2017 Drug cost: $62,998 (USD; Tot_Drug_Cst)2018 Drug cost: $154,088 (USD; Tot_Drug_Cst)2019 Drug cost: $291,624 (USD; Tot_Drug_Cst)2020 Drug cost: $208,631 (USD; Tot_Drug_Cst)2021 Drug cost: $429,729 (USD; Tot_Drug_Cst)2022 Drug cost: $1,150,925 (USD; Tot_Drug_Cst)2023 Drug cost: $1,989,457 (USD; Tot_Drug_Cst)2024 Drug cost: $2,200,484 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015N/RN/RN/R
20161134$3,322
2017101182$62,998
2018167504$154,088
2019169500$291,624
2020215528$208,631
20214581,096$429,729
20225681,518$1,150,925
20236131,718$1,989,457
20246991,957$2,200,484

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
11106Incision biopsy, first skin growth481541$95
17110Destruction of skin growth, 1-14 growths400490$65
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more1,1961,633$54
17000Destruction of precancer skin growth, 1 growth779992$33
17003Destruction of precancer skin growth, 2-14 growths5983,717$4

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
TremfyaGuselkumab422,268$557,445
Dupixent PenDupilumab1203,360$451,035
Skyrizi PenRisankizumab-Rzaa161,176$335,161
Humira(Cf)Adalimumab12336$151,743
Humira(Cf) PenAdalimumab15420$119,846

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.71$1,609Janssen Biotech, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Kenneth James Minielly, M.D.?

Tedicare shows public-source Medicare data for Kenneth James Minielly, M.D. (NPI 1699125062), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kenneth James Minielly, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Kenneth James Minielly, M.D.?

Kenneth James Minielly, M.D. is linked to KENTUCKY SKIN CANCER CENTER PLLC (billing NPI 1902302987) in the available physician profile data.

Does Kenneth James Minielly, M.D. have Open Payments data?

Kenneth James Minielly, M.D. has 71 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.